News for Chemomab Therapeutics Ltd. (CMMB)

Published at

Jun 3, 2025 4:00 PM

by gurufocus.com

positive

positive

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

””New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Cover

CMMB

Read more →
Published at

Jun 3, 2025 3:17 PM

by gurufocus.com

positive

positive

CMMB Gains New Patent Protections for Lead Product Nebokitug | CMMB Stock News

Chemomab Therapeutics (CMMB) has obtained new patent rights for its primary product, nebokitug, in China and Russia. These patents enhance the company's broad i

CMMB

Read more →
Published at

May 15, 2025 3:50 PM

by gurufocus.com

positive

positive

CMMB Achieves Milestones with FDA Pathway and Positive Trial Data | CMMB Stock News

In the first quarter of 2025, Chemomab (CMMB) marked significant achievements, underscoring potential advancements for the company and those affected by primary

CMMB

Read more →
Published at

May 15, 2025 3:00 PM

by gurufocus.com

positive

positive

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

””Reported Positive 48-Week Data from SPRING Trial””Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements acro

CMMB

Read more →
Published at

May 5, 2025 3:49 PM

by gurufocus.com

positive

positive

CMMB: Promising Phase 2 Trial Results for Nebokitug in PSC Treatment | CMMB Stock News

Chemomab Therapeutics (CMMB) has shared promising data from its Phase 2 SPRING trial concerning nebokitug, also known as CM-101, in the treatment of primary scl

CMMB

Read more →
Published at

May 5, 2025 3:00 PM

by gurufocus.com

positive

positive

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Signific

CMMB

Read more →
Published at

May 5, 2025 2:20 PM

by manilatimes.net

positive

positive

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

**media[614546]**

CMMB

Read more →
Published at

Apr 28, 2025 3:49 PM

by gurufocus.com

neutral

neutral

CMMB: Chemomab Therapeutics Unveils Promising Data on Nebokitug at EASL 2025 | CMMB Stock News

Chemomab Therapeutics (CMMB) has announced that it will present significant findings from two study abstracts at the upcoming EASL 2025 conference, scheduled fo

CMMB

Read more →
Published at

Apr 21, 2025 3:00 PM

by gurufocus.com

positive

positive

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., ( CMMB), a clinical stage biotechnology company developing innovative therap

CMMB

Read more →
Published at

Apr 21, 2025 2:21 PM

by manilatimes.net

positive

positive

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

**media[600378]**

CMMB

Read more →
Published at

Feb 3, 2025 1:00 PM

by gurufocus.com

positive

positive

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. ( CMMB) (Chemomab), a clinical stage biotechnology company developing innovativ

CMMB

Read more →
Published at

Dec 3, 2024 1:14 PM

by manilatimes.net

positive

positive

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

**media[481910]**

CMMB

Read more →
Published at

Dec 3, 2024 1:00 PM

by gurufocus.com

positive

positive

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

””Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companieswith ”Key, Near-Term, Potentially Stock-Moving Catalysts””” TEL

CMMB

Read more →
Published at

Nov 14, 2024 1:16 PM

by manilatimes.net

positive

positive

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

**media[465958]**

CMMB

Read more →
Published at

Oct 30, 2024 12:13 PM

by manilatimes.net

positive

positive

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

**media[451175]**

CMMB

Read more →
Published at

Oct 15, 2024 1:06 PM

by manilatimes.net

positive

positive

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

**media[436944]**

CMMB

Read more →
Published at

Sep 3, 2024 7:41 PM

by benzinga.com

mixed

mixed

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Intel (NASDAQ:INTC)

Shares of Recursion Pharmaceuticals, Inc. RXRX dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptom...

SIFY SHLS SGRP RXRX MSGM MNOV KROS DYN CMMB BNRG.TA AUUDW AUUD APDN AGMH AAOI 4875.T 0HGV.L WINTW WINT TDW-WT TDW PCVX NVCR NVAX.MX NVAX INTC.SN INTC.MX INTC INL.DE INCO.BR GERN FEDU CAR.MX CAR.BA CAR BOEI34.SA BOEI.BR BOE.L BCO.DE BA.SN BA.MX BA AP2.DE AMAT.MX AMAT A1MT34.SA 0IV3.L 0HK4.L 0A3S.L U2ST34.SA U.MX U MSCL.SN LITBN.MX LITB

Read more →
Published at

Aug 28, 2024 1:00 PM

by globenewswire.com

neutral

neutral

Chemomab Therapeutics to Present at September 2024 Investor Conferences

Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September...

CMMB

Read more →
Published at

Aug 26, 2024 3:39 PM

by investing.com

positive

positive

CMMB stock touches 52-week high at $1.58 amid market fluctuations By Investing.com

CMMB stock touches 52-week high at $1.58 amid market fluctuations

CMMB ANCN

Read more →
Published at

Aug 23, 2024 2:34 PM

by rttnews.com

mixed

mixed

Pre-market Movers: SQNS, MNTS, UBXG, PRTG, PTWO…

France-based semiconductor business Sequans Communications S.A. (SQNS) is up over 146 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

SQNS PTGEF PRTG MNTS UI RRGB OKYO.L EMMLF CMMB 0LI9.L WDAY.MX WDAY W1DA34.SA STAF KOPN GOVXW GOVX AIRI 0M18.L 0JRR.L

Read more →